You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cancer
  5. Ovarian cancer

Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer

  • Technology appraisal guidance
  • Reference number: TA284
  • Published:  22 May 2013
  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD)

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD) Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD)
25 March 2013
(249.92 Kb 12 sec)

Adobe Acrobat reader required.

  Adobe Acrobat reader required.

This page was last updated: 22 March 2013

Back to top